3D Medicines

3D Medicines Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing oncology therapies, particularly for cancer patients requiring long-term care. Founded in 2014 by Dr. John Z. Gong and Dr. Xiong Lei, the company operates primarily in China. Dr. Gong, the Chairman and CEO, has a background as a US FDA reviewer and held positions at BL Pharmaceutical and BeiGene before co-founding 3D Medicines. His partner, Dr. Xiong, founded the predecessor company in 2011, which was initially focused on oncology diagnostics. They met in 2013 and joined forces in 2014 to establish the biotechnology business line that evolved into the current company.

The company's business model integrates diagnostics, data, and drug development. It generates revenue through the sale of its commercialized core product, Envafolimab (brand name: ENWEIDA®), to pharmacy operating companies and distributors in China. Envafolimab, the world's first subcutaneous PD-L1 antibody, was approved in China in November 2021 and commercialized the following month for treating certain advanced solid tumors. By the end of May 2022, the drug had generated sales of ¥221 million (US$32 million), and cumulative sales surpassed RMB 1.7 billion within three years of its launch. The company's business network covers over 30 provinces, 1,300 hospitals, and 1,100 pharmacies in China.

3D Medicines went public on the Hong Kong Stock Exchange (HKG: 1244) on December 15, 2022, raising approximately US$52.5 million. A significant portion of the IPO proceeds was allocated to advance the clinical trials and commercialization of its drug candidates, with a major focus on Envafolimab. The company's pipeline includes the core product and 11 other drug candidates in various development stages. Its clinical laboratories are accredited by the College of American Pathologists (CAP) and certified by the Clinical Laboratory Improvement Amendments (CLIA). Beyond its core pharmaceutical focus, the company also develops diagnostic solutions; in 2020, it created RT-qPCR-based tests for SARS-CoV-2 and provides its products and services to over 60 countries.

Keywords: biopharmaceutical, oncology therapies, cancer treatment, drug development, precision medicine, Envafolimab, PD-L1 inhibitor, immuno-oncology, China, Hong Kong Stock Exchange, clinical trials, diagnostics, molecular diagnostics, subcutaneous injection, solid tumors, John Z. Gong, Xiong Lei, ENWEIDA, 1244.HK, cancer care